23 JUN. 2026
Sartorius and LFB BIOMANUFACTURING strengthen collaboration
Clients will benefit from collaboration and coordinated timelines that provide a streamlined and
seamless path from cell line development (CLD) to the clinic
The companies will de-risk and accelerate development for clients by combining proven
expertise and capabilities.
Sartorius and LFB BIOMANUFACTURING have announced an expansion of their collaboration with the aim of offering biopharmaceutical clients a comprehensive cell line development (CLD) to first batch of GMP drug substance service. The collaboration is designed to simplify and accelerate the path to the clinic.
Building on their successful collaboration launched in March 2024, this step will combine Sartorius expertise in CLD and master cell bank manufacturing with capabilities from LFB BIOMANUFACTURING, including upstream and downstream process development, analytical development and testing, and GMP drug substance manufacturing.
Together, the collaboration enables Sartorius and LFB BIOMANUFACTURING to gain access to each other’s respective platforms and technologies to offer a single path to the clinics.
“Our clients are at the center of this collaboration,” said Stefan Northoff, Head of Cell Line, Media, and Testing Solutions at Sartorius. “By collaborating with LFB BIOMANUFACTURING, we combine our cutting-edge CLD technology, including our recently launched genetically engineered host cell line, with expertise from LFB BIOMANUFACTURING in manufacturing, to help our clients achieve success as they take their therapeutics seamlessly to the clinic.”
“Through the strengthened collaboration between Sartorius and LFB BIOMANUFACTURING, our clients will gain access to a powerful combination of expertise spanning CLD, process optimization, and manufacturing,” said Herbert Guedegbe, Managing Director of LFB BIOMANUFACTURING. “This will enable our clients to move their innovative drug development programs forward with greater confidence and speed while improving patient outcomes.”
LFB BIOMANUFACTURING is a recognized CDMO with extensive experience developing therapeutic proteins, including monoclonal antibodies, Fc-fusions, bispecifics, and other complex biologics.
Sartorius brings more than 15 years of commercial CLD experience, having completed more than 330 projects, with more than 85 programs advancing into clinical development and over 10 achieving market approval.
The expanded collaboration reflects both companies’ long-term commitment to supporting biologics innovators with integrated, high-quality development solutions.
By building on proven synergies established through multiple successful projects, Sartorius and LFB BIOMANUFACTURING are creating a framework to support the next generation of therapeutic innovation.
LFB BIOMANUFACTURING, one of the key entities in the LFB group’s bioproduction activities, operates the Alès (Gard department, France) industrial site specialising in the manufacture of therapeutic proteins, mainly recombinant proteins and monoclonal antibodies by cell culture.
LFB BIOMANUFACTURING acts as a CDMO offering bioproduction services from cell line development to clinical and commercial manufacturing of medicinal products compliant with cGMP standards. On its FDA-approved industrial site in Alès, LFB BIOMANUFACTURING also manufactures a recombinant coagulation factor for the LFB group.
For more information, connect with LFB BIOMANUFACTURING via LinkedIn
LFB is a biopharmaceutical group that develops, manufactures, and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases.
Created in France in 1994, LFB today is a leading European company providing plasma-derived medicinal products to healthcare professionals. its mission is to offer patients new treatment options for unmet needs in three major therapeutic areas: immunology, haemostasis and intensive care.
LFB’s current market portfolio includes 15 biomedicinal products sold in about 30 countries.
Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry.
With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes.
The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and sustainably.
The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies.
In 2024, the company generated sales revenue of around 3.4 billion euros. Around 13,500 employees are working for customers around the globe.
